Document Detail

Ultra-short-course chemotherapy for spinal tuberculosis: five years of observation.
MedLine Citation:
PMID:  23053764     Owner:  NLM     Status:  MEDLINE    
PURPOSE: This study aimed to explore the feasibility of ultra-short-course chemotherapy in the treatment of spinal tuberculosis.
METHODS: One hundred and eighty-five patients with confirmed spinal tuberculosis and surgical indication were included. The chemotherapy regimen was 2SHRZ/XHRZ. According to the duration of the chemotherapy, the patients were divided into two groups, the ultra-short-course chemotherapy group with an average duration of 4.5 months, and the standard chemotherapy group with an average duration of 9 months. The same surgery was performed for patients in the two groups.
RESULTS: The duration of the follow-up ranged from 61 to 87 months, with an average of 69.1 months. Erythrocyte sedimentation rate and C-reactive protein, kyphosis and nerve function, recovery of work, and activities of daily living were not significantly different between the two groups before or after treatment; however, the aforementioned indices were significantly different before and after treatment within groups. There was no significant difference in postoperative bone graft healing between the two groups. The drug side effects were significantly different between the two groups.
CONCLUSIONS: With thorough focus debridement, bone grafting, and internal fixation, the efficacy of ultra-short chemotherapy was similar to that of standard chemotherapy for the treatment of spinal tuberculosis. The ultra-short-course chemotherapy can shorten the course of treatment and reduce drug side effects.
Zili Wang; Jiandang Shi; Guangqi Geng; Hongyan Qiu
Related Documents :
16904054 - Cytotoxic chemotherapy for prostate cancer: who and when?
22028054 - Prognostic value of positive human epidermal growth factor receptor 2 status and negati...
24833354 - Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab ...
22009364 - Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first...
21270454 - Pet and pet/ct of the neck lymph nodes improves risk prediction in patients with squamo...
2372764 - The prognostic significance of number of positive nodes in cervical carcinoma stages ib...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2012-10-11
Journal Detail:
Title:  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society     Volume:  22     ISSN:  1432-0932     ISO Abbreviation:  Eur Spine J     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  2013-07-22     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  9301980     Medline TA:  Eur Spine J     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  274-81     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antitubercular / administration & dosage,  therapeutic use*
Bone Transplantation
Cervical Vertebrae / surgery*
Drug Administration Schedule
Lumbar Vertebrae / surgery*
Middle Aged
Rifampin / administration & dosage,  therapeutic use*
Thoracic Vertebrae / surgery*
Treatment Outcome
Tuberculosis, Spinal / drug therapy*,  surgery
Reg. No./Substance:
0/Antibiotics, Antitubercular; VJT6J7R4TR/Rifampin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolated posterior instrumentation for selected cases of thoraco-lumbar spinal tuberculosis without ...
Next Document:  In vitro toxicity and antidiabetic activity of a newly developed polyherbal formulation (MAC-ST/001)...